Effect of Daily Ingestion of Konjac-origin Glucosylceramide on Cognitive function: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study-Pilot Study

Not Applicable

• Conditions: Healthy adults

• Registration Number: JPRN-UMIN000039292
• Lead Sponsor: Hokkaido Information University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-01-28
• Study Completion: 2020-10-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1.Subjects whose MMSE score is <= 23 points. 2.Subjects with unusually high and/or low plasma amyloid be-ta. 3.Subjects who are under medication for dementia, Alzheimer's disease, psychiatric disorder and cerebrovascular disease. 4.Subjects with a history of (or suspected) psychiatric disorder and cerebrovascular disease. 5. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 6. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 7. Subjects with unusually high and/or low blood pressure and/or abnormal physical data and hematological data. 8. Subjects with severe anemia. 9. Pre- or post-menopausal women complaining of obvious physical changes. 10. Subjects with dysphagia. 11. Subjects who are at risk of having allergic reactions to drugs or foods especially based on gelatin, mango, urushi, pistachio, cashew nut, latex rubber and birch. 12. Subjects who regularly take medicine, functional foods, and/or supplements which would affect cognitive function. 13. Heavy smokers, alcohol addicts or subjects with disordered lifestyle. 14. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the current study. 15. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 16. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified